Related Experiment Videos
Potential limitations in using minor histocompatibility antigen-specific cytotoxic T cells for targeting solid tumor
Mikinori Miyazaki1, Yoshiki Akatsuka, Tetsuya Nishida
1Division of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Clinical Immunology (Orlando, Fla.)
|June 14, 2003
Summary
Aberrantly expressed KIAA0223 (HA-1 antigen) in solid tumors can be targeted by cytotoxic T lymphocytes (CTLs). However, impaired antigen processing may allow tumors to evade immune detection.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- KIAA0223, encoding the minor histocompatibility antigen HA-1, is aberrantly expressed in some solid tumors.
- Previous understanding suggested HA-1 expression was limited to hematopoietic cells.
Purpose of the Study:
- To determine the significance of aberrant KIAA0223 expression in tumor immunity.
- To assess the cytotoxic activity of HA-1(H)-specific cytotoxic T lymphocytes (CTLs) against solid tumor cell lines.
Main Methods:
- Utilized (51)Cr release assays to measure CTL activity.
- Tested cytotoxicity against solid tumor cell lines expressing KIAA0223.
- Investigated tumor cell line susceptibility after IFN-gamma and TNF-alpha treatment.
- Analyzed HA-1 peptide generation and presentation.
Main Results:
- Five of seven tested solid tumor cell lines expressing KIAA0223 were lysed by HA-1(H)-specific CTLs when HLA-A*0201 was adequately expressed.
- One resistant cell line became susceptible after cytokine treatment; another required peptide pulsing.
- In most cases, HA-1(H) peptide was correctly processed and presented.
- Impaired antigen processing and presentation were observed in some cell lines.
Conclusions:
- Aberrant expression of KIAA0223 in solid tumors presents a potential target for CTL-mediated immunotherapy.
- Mechanisms of impaired antigen processing and presentation can lead to tumor immune escape.
- Further investigation into antigen processing pathways is warranted for effective cancer immunotherapy.